PE Tech Report


Like this article?

Sign up to our free newsletter

Hatteras names new partner

Hatteras Venture Partners has named Sir Andrew Witty as a Venture Partner.

Witty will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the ever-changing global health care industry. In addition, he will provide leadership counsel to Hatteras’ portfolio companies.  
“We are thrilled to welcome Andrew to Hatteras Venture Partners. He brings unparalleled strategic insights and extensive industry experience to the firm and to our portfolio of emerging companies,” says Bob Ingram, General Partner of Hatteras Venture Partners. “Having had the pleasure of serving as Andrew’s mentor when I was CEO of Glaxo, it is hard to fully express my pride in having him join our dynamic team of company builders.”
Witty is also Chancellor of the University of Nottingham in England and serves on the boards of UnitedHealth Group and G1 Therapeutics, Inc. He was Chief Executive Officer of GlaxoSmithKline, plc (GSK) from 2008 until he retired in 2017. He joined GSK in 1985 and served in various senior roles in the UK, the US, South Africa and Singapore. In 2012, Witty was knighted for services to the economy and the UK pharmaceutical industry.
“Joining Hatteras gives me an exciting new opportunity to nurture amazing science for the benefit of patients,” says Witty. “The firm has an outstanding track record of finding novel science in the halls of academia and translating that science into successful companies. I cannot think of a better objective in the evolving health care environment than capitalising this kind of innovation.”     

Like this article? Sign up to our free newsletter




Blackstone Private Equity